Total Sialic Acid as a Tumor Marker for Oral Cancer

Xing, Ruiyun; Zs, Wang; Li, C-Q.; Qy, Tang; Cb, Jiang; Yz, Zhang

doi:10.1177/172460089400900406

Cited by 14 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggested that malignant transformation brings changes in cell surface glycoconjugates, which is in accordance with earlier reports (10). Elevations in the levels of sialic acid appeared to reflect tumour burden and correlated well with the stage of the primary lesion and presence of distant metastasis (4, 10, 17, 21). We also observed significant progressive elevations in serum TSA and LSA values in oral cancer with stage of the malignant disease.…”

Section: Discussionmentioning

confidence: 98%

Clinical significance of total and lipid bound sialic acid levels in oral pre‐cancerous conditions and oral cancer

Rajpura

Patel

Chawda

et al. 2005

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Clinical significance of total and lipid bound sialic acid levels in oral pre‐cancerous conditions and oral cancer

Rajpura

Patel

Chawda

et al. 2005

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…To our knowledge, no reliable circulating tumor marker currently is available for use in the treatment of patients with oral SCC, despite efforts to establish such a marker 26–30, 37. This is a major drawback in the field because the importance of the early detection of these lesions cannot be overemphasized.…”

Section: Discussionmentioning

confidence: 99%

“…Tumor markers, which have been accepted as a valuable tool for diagnosis, prognosis, and treatment monitoring in recent years,12–18 could be an easy and desirable means of achieving this purpose. Various tumor markers have been examined for their value in detecting head and neck and/or oral carcinoma 19–31. However, the main drawback of these markers was their low sensitivity for head and neck carcinoma, which rendered them useless for clinical purposes.…”

mentioning

confidence: 99%

Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma

Nagler

Barak²,

Peled

et al. 1999

Cancer

View full text Add to dashboard Cite

BACKGROUND Mucosal oral squamous cell carcinoma (SCC) accounts for 3–5% of all reported cancers, with a 5‐year survival rate of approximately 50%. Unfortunately, current detection means are of no value in diagnosing lesions early enough for cure, especially when they recur after resection. Postoperative radiotherapy and/or covering the resection site with reconstructive flaps (regional or free vascularized) often makes early diagnosis an impossible task. METHODS The authors examined the detection and treatment monitoring capacity of two relatively new tumor markers in the serum of SCC patients, comparing their levels with those in patients with other oral/perioral malignancies or benign oral tumors and with disease free, posttreatment SCC patients and healthy controls. RESULTS Values of sensitivity, specificity, and positive and negative prediction for Cyfra 21‐1 were 96%, 87%, 93%, and 53%, respectively, whereas those for tissue polypeptide specific antigen (TPS) were 69%, 87%, 93%, and 54%, respectively. Approximately 2–3 weeks after resection of the SCC lesion, Cyfra 21‐1 and TPS levels were reduced by 47% (P ≤ 0.003) and 36% (P ≤ 0.041), respectively. Cyfra 21‐1 levels in SCC patients were significantly greater than those of healthy patients by 73% (P ≤ 0.0001), patients with benign tumors by 74% (P ≤ 0.0003), and patients in disease remission by 66% (P ≤ 0.0002). Similarly, the TPS levels of SCC patients were significantly greater than those of healthy patients by 59% (P ≤ 0.0005), patients with benign tumors by 55% (P ≤ 0.0001), and patients in disease remission by 59% (P ≤ 0.0001). In two patients, a second, new SCC lesion was diagnosed within the follow‐up period, with increased tumor markers noted concomitantly with the diagnosis. CONCLUSIONS The accumulated data point to the suitability of the clinical usage of these two markers, especially Cyfra 21‐1, in the early detection of oral SCC lesions (primary, recurrent, or secondary) as well as for treatment monitoring. These results may open new avenues for the diagnosis and follow‐up of these patients and hopefully improve their treatment outcome. Cancer 1999;85:1018–25. © 1999 American Cancer Society.

show abstract

“…Increased levels of serum TSA and/or LSA have been observed in various patient groups suffering from advanced ovarian carcinoma [52], brain tumours [53][54][55], leukaemia [56], lung cancer [57], cervical cancer [58], carcinoma of the hypopharynx and larynx [59], rectal, large intestinal and bronchogenic cancers [60], malign pleural effusion [61], oral cancer [62], melanoma [63], stomach, breast [64], colorectal, gall bladder cancer [65], thyroid and Hodgkin's cancers [55], sarcoma [52], and endometrial cancer [66]. For levels of TSA, LSA, TSA/total protein and protein-bound SA in sera from cancer patients and their control subjects (see Table 4).…”

Section: Sa Concentrations In Malignanciesmentioning

confidence: 99%

“…The increase in SA has been observed to correlate positively with tumour burden [55,58,62,63,65,67,68], i.e. the level of metastasis.…”

Section: Sa Concentrations In Malignanciesmentioning

confidence: 99%

Occurrence of sialic acids in healthy humans and different disorders

Sillanaukee

Pönniö

Jä̈askëlainen

1999

Eur J Clin Investigation

230

166

View full text Add to dashboard Cite

Sialic acid (SA), N-acetylated derivatives of neuraminic acid, play a central role in the biomedical functioning of humans. The normal range of total sialic acid (TSA) level in serum/plasma is 1.58-2.22 mmol L-1, the free form of SA only constituting 0.5-3 mumol L-1 and the lipid-associated (LSA) forms 10-50 mumol L-1. Notably, considerably higher amounts of free SA are found in urine than in serum/plasma (approximately 50% of the total SA). In inherited SA storage diseases such as Salla's disease, SA levels are elevated many times over, and their determination during clinical investigation is well established. Furthermore, a number of reports describe elevated SA levels in various other diseases, tentatively suggesting broader clinical utility for SA markers. Increased SA concentrations have been reported during inflammatory processes, probably resulting from increased levels of richly sialylated acute-phase glycoproteins. A connection between increased SA levels and elevated stroke and cardiovascular mortality risk has also been reported. In addition, SA levels are slightly increased in cancer, positively correlating with the degree of metastasis, as well as in alcohol abuse, diabetes, chronic renal failure and chronic glomerulonephritis. Several different mechanisms are assumed to underlie the elevated SA concentrations in these disorders. The apparent non-specificity of SA to a given disease limits the potential clinical usefulness of SA determination. In addition, some non-pathological factors, such as aging, pregnancy and smoking, may cause changes in SA concentrations. The absolute increases in SA levels are also rather small (save those in inherited SA storage disorders); this further limits the clinical potential of SA as a marker. Tentatively, SA markers might serve as adjuncts, when combined with other markers, in disease screening, disease progression follow-up, and in the monitoring of treatment response. To become clinically useful, however, the existing SA determination assays need to be considerably refined to reduce interferences, to be specific for certain SA forms, and to be more easy to use.

show abstract

Total Sialic Acid as a Tumor Marker for Oral Cancer

Cited by 14 publications

References 11 publications

Clinical significance of total and lipid bound sialic acid levels in oral pre‐cancerous conditions and oral cancer

Clinical significance of total and lipid bound sialic acid levels in oral pre‐cancerous conditions and oral cancer

Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma

Occurrence of sialic acids in healthy humans and different disorders

Contact Info

Product

Resources

About